Skip to content

MONA LISA

Active
Public limited companyfounded 1995active for 31 yearsKapelstraat 1, 3540 Herk-de-Stad, BelgiumKBO/BCE: BE 0456.182.981
Summary

MONA LISA has been active since 1995 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.0m and a net result of -€83,430. Equity remains stable across the filed financial years (±1.2% per year). Its solvency ranks better than 82% of 141 sector peers (NACE 32, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Manufacture of medical and dental instruments and supplies
NACE 32500Wholesale of pharmaceutical and medical goods NACE 46460
#5 company by total assets in Herk-de-Stad, Manufacturing sector1 site
Size
€4.2mturnover 2025
Staff
9.7 FTE
Equity
€2.0m
Loss
-€83,430
Net result +86%: other schema
Financial health
95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Parent
Alphamed Arzneimittel Gmbh & Co Kg
  • Alphamed Arzneimittel Gmbh & Co KGeManaging director · permanent representative Friederik Hrubesch-Mohringer
  • Eurim-Pharm Vertriebs Gmbh & Co KGDirector · permanent representative Wolfgang Stallmayer
  • Magdalena HrubeschDirector
Accounts 32 days early1 of 12 deeds read
Why 95raises riskLoss of €83,430, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 3.71, cash €825,883Founded in 1995Equity €2.0m (79.0% of total assets)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 63% of its sector peers (NACE 32, micro)
Financial strength · tick = 2024
Strong
Solvency 100+13
equity 79.0% of total assets
Liquidity 84+1
short-term debt 20.5% · cash 32.3%
Profitability 15+15
return on assets -3.3%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (1,138 companies, NACE 32, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025lowest value 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: 0.2%▲ +0.2 percentage points vs 07-2025 09-2025: 0.2%● unchanged vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.3%▲ +0.1 percentage points vs 02-2026 04-2026: 0.3%● unchanged vs 03-2026 05-2026: 0.3%● unchanged vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026highest value 07-2026: 0.1%▼ -0.2 percentage points vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €190,000 on 30-day terms is acceptable
Liquidity ample (current ratio 3.71, compared with 2.16 in 2024; short-term debt: 20.5% and cash: 32.3% of total assets), and 21% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 32, micro): better than 90% on solvency, 83% on liquidity, 19% on profitability and 62% on growth.

The bankruptcy probability was computed on 09-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 3.71, cash €825,883
NBB · annual accounts
raises risk · Loss of €83,430, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Founded in 1995
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
lowers risk · Equity €2.0m (79.0% of total assets)
NBB · annual accounts
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
1819202122232425
2018 to 2025 · latest year -€83,430
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
32 days early
2024
20 days early
2023
29 days late
2022
4 days late
2021
2 days late
2020
31 days early
2019
38 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 12 days before the deadline; the sector median (NACE 32) for financial year 2024 is 2 days before the deadline, and 40% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 2 August (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
10-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Permanent representatives: Friederik Hrubesch-Mohringer and Wolfgang…Appointments: Alphamed Arzneimittel Gmbh &…
  3. Annual accounts filedfinancial year 2024 · abbreviated…

Key points

  • Positive: Result rose in 2025different schema filed ▲ 85.9% View
  • Caution: Among the weakest 19% on net resultsector median €37,411 · 140 companies -€83,430 View
  • New directorslatest change 22-12-2025 · 3 in office 3 joined View
  • Controlled by Alphamed Arzneimittel Gmbh &… parent View
  • Caution: 2 loss-making years in a rowloss financial year 2025 -€83,430 View

By topic

Financials

Financial year
2025
Turnover
€4.2m
Loss
-€83,430
Solvency
79.0%
Turnover▲ 36.2%
Net result
20182025
Go to Financials

Board & ownership

Board
3 members
Parent
Alphamed Arzneimittel Gmbh &…
  • Alphamed Arzneimittel Gmbh & Co KGeManaging director
  • Eurim-Pharm Vertriebs Gmbh & Co KGDirector
  • Magdalena HrubeschDirector
Go to Board & ownership

Timeline

Events
33
Since
1997
Next accounts
by 31-07-2027
  1. 31-12-2024Weakest financial year
  2. 29-08-2024Annual accounts filed
  3. 04-08-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of medical and dental instruments and suppliesNACE 32500
Founded
02-10-1995
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
28
Annual meeting
Third Monday of June at 19:00
Purpose
De verwerving voor eigen rekening van participaties, onder welke vorm het ook zij, in de…
Go to Articles of association

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.